Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ziping Ye, Jia Ma, Fuyao Liu, Chen Wang, Ziyang Zhou & Lihua Sun. (2022) A systematic review and meta-regression of studies eliciting willingness-to-pay per quality-adjusted life year in the general population. Expert Review of Pharmacoeconomics & Outcomes Research 22:1, pages 53-61.
Read now
Read now
Nathan WD Lamond & Tallal Younis. (2014) Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations. International Journal of Women's Health 6, pages 509-521.
Read now
Read now
Montarat Thavorncharoensap, Yot Teerawattananon, Sirin Natanant, Wantanee Kulpeng, Jomkwan Yothasamut & Pitsaphun Werayingyong. (2013) Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?. ClinicoEconomics and Outcomes Research 5, pages 29-36.
Read now
Read now
John FP Bridges & Christine Buttorff. (2010) What outcomes should US policy makers compare in comparative effectiveness research?. Expert Review of Pharmacoeconomics & Outcomes Research 10:3, pages 217-220.
Read now
Read now
Articles from other publishers (27)
Christian R. C. Kouakou & Thomas G. Poder. (2021) Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression. The European Journal of Health Economics 23:2, pages 277-299.
Crossref
Crossref
Mehdi Shiva, Cheng Wei, Hassan Molana & Ghulam Nabi. (2022) Cost-Effectiveness of Prostate Cancer Detection in Biopsy-Naïve Men: Ultrasound Shear Wave Elastography vs. Multiparametric Diagnostic Magnetic Resonance Imaging. Healthcare 10:2, pages 254.
Crossref
Crossref
Praveen Hariharan, Muhammad Bilal Tariq, James C. Grotta & Alexandra L. Czap. (2022) Mobile Stroke Units: Current Evidence and Impact. Current Neurology and Neuroscience Reports 22:1, pages 71-81.
Crossref
Crossref
Afschin Gandjour. (2021) The price of curing cancer. BMC Health Services Research 21:1.
Crossref
Crossref
Vassileios Fragoulakis, George P. Patrinos & Christina Mitropoulou. 2020. Applied Genomics and Public Health. Applied Genomics and Public Health
287
304
.
Jason Shafrin, Michelle Skornicki, Michelle Brauer, Julie Villeneuve, Michael Lees, Nadine Hertel, John R. Penrod & Jeroen Jansen. (2018) An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?. Health Policy 122:6, pages 607-613.
Crossref
Crossref
STEVEN J. FIRTH. (2018) The Quality Adjusted Life Year: A Total-Utility Perspective. Cambridge Quarterly of Healthcare Ethics 27:2, pages 284-294.
Crossref
Crossref
Belen Zapata-Diomedi, Lucy Gunn, Billie Giles-Corti, Alan Shiell & J. Lennert Veerman. (2018) A method for the inclusion of physical activity-related health benefits in cost-benefit analysis of built environment initiatives. Preventive Medicine 106, pages 224-230.
Crossref
Crossref
Boshen Jiao, Zafar Zafari, Brian Will, Kai Ruggeri, Shukai Li & Peter Muennig. (2017) The Cost-Effectiveness of Lowering Permissible Noise Levels Around U.S. Airports. International Journal of Environmental Research and Public Health 14:12, pages 1497.
Crossref
Crossref
Martina Garau & Nancy J. Devlin. 2017. Multi-Criteria Decision Analysis to Support Healthcare Decisions. Multi-Criteria Decision Analysis to Support Healthcare Decisions
277
298
.
T. Younis, D. Rayson, S. Jovanovic & C. Skedgel. (2016) Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review. Breast Cancer Research and Treatment 159:3, pages 425-432.
Crossref
Crossref
Sanjeewa Kularatna, Dennis Petrie, Paul A Scuffham & Joshua Byrnes. (2016) Health Auctions: a Valuation Experiment (HAVE) study protocol: Table?1. BMJ Open 6:4, pages e009081.
Crossref
Crossref
Scott Grosse. (2015) Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis. Healthcare 3:4, pages 1133-1157.
Crossref
Crossref
Linda Ryen & Mikael Svensson. (2015) The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature. Health Economics 24:10, pages 1289-1301.
Crossref
Crossref
Lan Gao, Li Xia, Song-Qing Pan, Tao Xiong & Shu-Chuen Li. (2015) Health-Related Quality of Life and Willingness to Pay per Quality-Adjusted Life-Year Threshold—A Study in Patients with Epilepsy in China. Value in Health Regional Issues 6, pages 89-97.
Crossref
Crossref
Khachapon Nimdet, Nathorn Chaiyakunapruk, Kittaya Vichansavakul & Surachat Ngorsuraches. (2015) A Systematic Review of Studies Eliciting Willingness-to-Pay per Quality-Adjusted Life Year: Does It Justify CE Threshold?. PLOS ONE 10:4, pages e0122760.
Crossref
Crossref
Mark Pennington, Rachel Baker, Werner Brouwer, Helen Mason, Dorte Gyrd Hansen, Angela Robinson & Cam Donaldson. (2015) Comparing WTP Values of Different Types of QALY Gain Elicited from the General Public. Health Economics 24:3, pages 280-293.
Crossref
Crossref
Ana Bobinac, N. Job A. van Exel, Frans F. H. Rutten & Werner B. F. Brouwer. (2012) VALUING QALY GAINS BY APPLYING A SOCIETAL PERSPECTIVE. Health Economics 22:10, pages 1272-1281.
Crossref
Crossref
Ana Bobinac, N. Job A. van Exel, Frans F.H. Rutten & Werner B.F. Brouwer. (2012) Inquiry into the Relationship between Equity Weights and the Value of the QALY. Value in Health 15:8, pages 1119-1126.
Crossref
Crossref
Nathan W. D. Lamond, Chris Skedgel, Daniel Rayson, Lynn Lethbridge & Tallal Younis. (2012) Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Research and Treatment 133:3, pages 1115-1123.
Crossref
Crossref
Mark Sculpher & Karl Claxton. (2012) Real Economics Needs to Reflect Real Decisions. PharmacoEconomics 30:2, pages 133-136.
Crossref
Crossref
Alwin JeyakumarTallal Younis. (2012) Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations. Clinical Medicine Insights: Oncology 6, pages CMO.S6460.
Crossref
Crossref
Steven Simoens. 2012. Pharmacoinformatics and Drug Discovery Technologies. Pharmacoinformatics and Drug Discovery Technologies
92
109
.
Javier Soto ÁlvarezJavier Soto Álvarez. 2012. Evaluación económica de medicamentos y tecnologías sanitarias:. Evaluación económica de medicamentos y tecnologías sanitarias:
305
324
.
Javier Soto ÁlvarezJavier Soto Álvarez. 2012. Evaluación económica de medicamentos y tecnologías sanitarias:. Evaluación económica de medicamentos y tecnologías sanitarias:
147
170
.
Fei-Li Zhao, Ming Yue, Hua Yang, Tian Wang, Jiu-Hong Wu & Shu-Chuen Li. (2011) Willingness to Pay per Quality-Adjusted Life Year: Is One Threshold Enough for Decision-Making?. Medical Care 49:3, pages 267-272.
Crossref
Crossref
Sarah Karlsberg Schaffer, Jon Sussex, Nancy Devlin & Andrew Walker. (2013) Searching for Cost-Effectiveness Thresholds in NHS Scotland. SSRN Electronic Journal.
Crossref
Crossref